Xinhua Pharmaceuticals: Obtained registration certificate for Oseltamivir phosphate oral suspension.

Xinhua Pharmaceutical announced that it has recently received the "Drug Registration Certificate" for the approval and issuance of phosphoric acid oseltamivir suspension by the National Medical Products Administration. The drug is an over-the-counter medication, classified as a 3rd class chemical medication, used for the treatment of influenza types A and B in patients 2 weeks and older, as well as for prevention in individuals aged 1 year and older. The company submitted the application materials in March 2024 and received approval in December 2025. In 2024, the sales of phosphoric acid oseltamivir related preparations in public medical institutions in China were approximately 5.9 billion yuan. The approval has enriched the company's antiviral drug product line and enhanced its overall competitiveness, but sales are subject to uncertainties due to factors such as policies and market conditions.